Nick Li

Nick Li

Auto-generated profile, based on publicly available information

Nick Li

Cell Communication Laboratory, Department of Oncology, University College London Cancer Institute, 72 Huntley Street, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2018 in BJS Open
Verified
Journal Article
Open access
PDF file
NLN. Li
N. Li
DMD. Marshall
D. Marshall
MSM. Sykes
M. Sykes
PMP. McCulloch
P. McCulloch
JSJ. Shalhoub
J. Shalhoub
MMM. Maruthappu
M. Maruthappu
Teamwork in the operating theatre is becoming increasingly recognized as a major factor in clinical outcomes. Many tools have been developed to measure teamwork. Most fall into two categories: self-assessment by theatre staff and assessment by observers. A critical and comparative analysis of the validity and reliability of these tools is lacking. MEDLINE and Embase databases were searched following PRISMA guidelines. Content validity was assessed using measurements of inter-rater agreement, predictive validity and multisite reliability, and interobserver reliability using statistical measures of inter-rater agreement and reliability. Quantitative meta-analysis was deemed unsuitable. Forty-eight articles were selected for final inclusion; self-assessment tools were used in 18 and observational tools in 28, and there were two qualitative studies. Self-assessment of teamwork by profession varied with the profession of the assessor. The most robust self-assessment tool was the Safety Attitudes Questionnaire (SAQ), although this failed to demonstrate multisite reliability. The most robust observational tool was the Non-Technical Skills (NOTECHS) system, which demonstrated both test–retest reliability (P > 0·09) and interobserver reliability (Rwg = 0·96). Self-assessment of teamwork by the theatre team was influenced by professional differences. Observational tools, when used by trained observers, circumvented this.

16 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
TSTamara M Sirey
Tamara M Sirey
KRKenny Roberts
Kenny Roberts
WHWilfried Haerty
Wilfried Haerty
OROscar Bedoya Reina
Oscar Bedoya Reina
SRSebastian Rogatti-Granados
Sebastian Rogatti-Granados
CPChris P Ponting
Chris P Ponting
To generate energy efficiently, the cell is uniquely challenged to co-ordinate the abundance of electron transport chain protein subunits expressed from both nuclear and mitochondrial genomes. How an effective stoichiometry of this many constituent subunits is co-ordinated post-transcriptionally remains poorly understood. Here we show that Cerox1 , an unusually abundant cytoplasmic long noncoding RNA (lncRNA), modulates the levels of mitochondrial complex I subunit transcripts in a manner that requires binding to microRNA-488-3p. Increased abundance of Cerox1 cooperatively elevates complex I subunit protein abundance and enzymatic activity, decreases reactive oxygen species production, and protects against the complex I inhibitor rotenone. Cerox1 function is conserved across placental mammals: human and mouse orthologues effectively modulate complex I enzymatic activity in mouse and human cells, respectively. Cerox1 is the first lncRNA demonstrated, to our knowledge, to regulate mitochondrial oxidative phosphorylation (OXPHOS) and, with miR-488-3p, represent novel targets for the modulation of complex I activity.

18 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CMCorinne Molyneux
Corinne Molyneux
RORhianna O'SUllivan
Rhianna O'SUllivan
EMEoghan Mulholland
Eoghan Mulholland
JMJoshua William Moore
Joshua William Moore
NLNick Li
Nick Li
CTChristopher J. Tape
Christopher J. Tape
Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.

24 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
NLNick Li
Nick Li
FIFiza Mf Ishaqwalab
Fiza Mf Ishaqwalab
CTChristopher J. Tape
Christopher J. Tape
SPSee Pdf
See Pdf
Rectal cancers are often treated with neoadjuvant chemoradiotherapy (CRT), yet 85% of patients do not achieve a pathological complete response. To identify the molecular determinants of CRT response, we profiled the single-cell signalling, DNA-damage, cell-cycle, apoptotic, and cell-fate responses of 2,769 patient-derived organoid cultures treated with CRT, cancer-associated fibroblasts (CAFs), and signal-rewiring agents. We find that CRT response is determined by stem cell-fate. CRT triggers comparable DNA-damage in isogenic proliferative (proCSC) and revival (revCSC) colonic stem cells, but proCSC retain damage and die whereas revCSC resolve damage and persist. Both CRT and CAFs drive proCSC to a common treatment-resistant revCSC fate and high revCSC predicts worse survival in patients. Pharmacologically constraining stem-cell plasticity increases CRT sensitivity, and Spatial Perturbation of ARrayed Tumour Assembloids (SPARTA) confirms YAP/TEAD inhibition improves chemotherapy responses in human stromal-tumour models. These results suggest that cancer cell-fate, not genotoxic damage itself, ultimately governs response to standard-of-care chemoradiotherapy.

15 July 2026 in bioRxiv
Verified
Preprint
Open access
NLNick Li
Nick Li
FIFiza Ishaqwala
Fiza Ishaqwala
TWThomas A. Wright
Thomas A. Wright
AWAlistair Wilkinson
Alistair Wilkinson
PVPetra Vlckova
Petra Vlckova
CTChristopher J. Tape
Christopher J. Tape
SUMMARY: Rectal cancers are often treated with neoadjuvant chemoradiotherapy (CRT), yet 85% of patients do not achieve a pathological complete response. To identify the molecular determinants of CRT response, we profiled the single-cell signalling, DNA-damage, cell-cycle, apoptotic, and cell-fate responses of 2,769 patient-derived organoid cultures treated with CRT, cancer-associated fibroblasts (CAFs), and signal-rewiring agents. We find that CRT response is determined by stem cell-fate. CRT triggers comparable DNA-damage in isogenic proliferative (proCSC) and revival (revCSC) colonic stem cells, but proCSC retain damage and die whereas revCSC resolve damage and persist. Both CRT and CAFs drive proCSC to a common treatment-resistant revCSC fate and high revCSC predicts worse survival in patients. Pharmacologically constraining stem-cell plasticity increases CRT sensitivity, and Spatial Perturbation of ARrayed Tumour Assembloids (SPARTA) confirms YAP/TEAD inhibition improves chemotherapy responses in human stromal-tumour models. These results suggest that cancer cell-fate, not genotoxic damage itself, ultimately governs response to standard-of-care chemoradiotherapy. HIGHLIGHTS: Rectal cancer stem cell-fate determines chemoradiotherapy-induced apoptosis proCSCs retain DNA-damage and die, whereas revCSCs repair damage and persist CAFs and chemoradiotherapy converge on a common chemo-radioresistant revCSC state SPARTA reveals TEAD inhibition blocks DNA-repair persisters in stromal assembloids